ImmuneOnco’s IMM2520 obtained approval of clinical research from the US FDA
On December 14, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the newly-developed bispecific antibody-receptor recombinant protein drug (project number: IMM2520), targeting CD47 and PD-L1, obtained clinical research approval from the US FDA. This is the fourth IND approval for the company to date (others include IMM0306, IMM2902 and IMM40H), and it is another important milestone in the company's development. Previously, IMM2520 was granted a Japanese patent and orther patents in China, the European union and the United States has been submitted. In November 2022, the IMM2520 has been approved by NMPA to carry out clinical trials. The approval by FDA for clincal trials strenthens the development of IMM2520 globally and consolidates the company’s leading position in the field of drug development for targeting CD47 and bispecific antibody research.
Dr. Tian, Wenzhi, Founder and Chairman of ImmuneOnco, said:
"We are very pleased that our IMM2520 program has received clinical trial research approval from the US FDA. IMM2520 is an antibody-receptor recombinant protein (mAb-Trap) that targets both CD47 and PD-L1. We believe that IMM2520 has great clinical development value, and we will actively promote clinical research and strive to bring it to market as soon as possible, so as to benefit the cancer patients."
- Last：The phase II clinical study of ImmuneOnco’s IMM01 combined with azacitidine for first line treatment of high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) completed the enrollment of patients
- Next：Phase II clinical study of ImmuneOnco IMM01 combined with PD-1 monoclonal antibody against solid tumors and lymphomas officially launched